Pullen Investment Management LLC Cuts Holdings in Revvity Inc. $RVTY

Pullen Investment Management LLC trimmed its position in shares of Revvity Inc. (NYSE:RVTY) by 11.6% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,149 shares of the company’s stock after selling 415 shares during the quarter. Pullen Investment Management LLC’s holdings in Revvity were worth $305,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of RVTY. UMB Bank n.a. lifted its holdings in shares of Revvity by 138.8% during the 2nd quarter. UMB Bank n.a. now owns 406 shares of the company’s stock valued at $39,000 after buying an additional 236 shares during the period. CVA Family Office LLC lifted its holdings in shares of Revvity by 79.0% during the 2nd quarter. CVA Family Office LLC now owns 410 shares of the company’s stock valued at $40,000 after buying an additional 181 shares during the period. New Age Alpha Advisors LLC bought a new position in shares of Revvity during the 1st quarter valued at $44,000. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Revvity by 25.3% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 694 shares of the company’s stock valued at $73,000 after buying an additional 140 shares during the period. Finally, Cary Street Partners Investment Advisory LLC bought a new position in shares of Revvity during the 1st quarter valued at $75,000. 86.65% of the stock is owned by institutional investors.

Revvity Price Performance

Shares of Revvity stock opened at $98.91 on Friday. Revvity Inc. has a one year low of $81.36 and a one year high of $129.50. The stock’s fifty day moving average is $89.38 and its 200 day moving average is $92.43. The stock has a market cap of $11.48 billion, a P/E ratio of 41.91, a P/E/G ratio of 3.30 and a beta of 0.98. The company has a debt-to-equity ratio of 0.43, a quick ratio of 2.75 and a current ratio of 3.33.

Revvity (NYSE:RVTY) last posted its quarterly earnings results on Monday, July 28th. The company reported $1.18 EPS for the quarter, beating analysts’ consensus estimates of $1.14 by $0.04. The business had revenue of $720.28 million for the quarter, compared to analysts’ expectations of $711.26 million. Revvity had a return on equity of 7.66% and a net margin of 10.19%.The business’s quarterly revenue was up 4.1% on a year-over-year basis. During the same period last year, the firm earned $1.22 earnings per share. Revvity has set its FY 2025 guidance at 4.850-4.950 EPS. Sell-side analysts anticipate that Revvity Inc. will post 4.94 earnings per share for the current year.

Revvity Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 6th. Shareholders of record on Friday, January 16th will be issued a dividend of $0.07 per share. The ex-dividend date of this dividend is Friday, January 16th. This represents a $0.28 dividend on an annualized basis and a yield of 0.3%. Revvity’s dividend payout ratio (DPR) is currently 11.86%.

Analyst Ratings Changes

Several research firms have recently weighed in on RVTY. Robert W. Baird set a $122.00 price target on Revvity in a report on Friday. Stifel Nicolaus lowered their price target on Revvity from $120.00 to $110.00 and set a “hold” rating on the stock in a report on Tuesday, July 29th. Barclays lowered their price target on Revvity from $110.00 to $100.00 and set an “overweight” rating on the stock in a report on Thursday, October 2nd. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Revvity in a report on Saturday. Finally, Wall Street Zen cut Revvity from a “buy” rating to a “hold” rating in a report on Sunday, August 3rd. Nine analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $116.38.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.